華潤雙鶴(600062.SH)：上半年淨利潤10.47億元，同比增長6.28% 擬10派1元
格隆匯8月22日丨華潤雙鶴(600062.SH)公佈2024年半年度報吿，2024年上半年公司營收利潤雙增長：報吿期實現營業收入59.29億元，同比增長1.46%；歸屬於上市公司股東的淨利潤10.47億元，同比增長6.28%；歸屬於上市公司股東的扣除非經常性損益的淨利潤9.22億元，同比增長27.58%；基本每股收益1.0199元。公司擬向全體股東每10股派發現金紅利1.00元(含税)。
目前公司的銷售網絡遍佈全國，非輸液業務擁有兩千餘家商業客户，覆蓋醫院、城市社區中心/站點以及農村基層醫療終端十五萬餘家，覆蓋藥店三十餘萬家，還與百餘家百強連鎖藥店開展合作。輸液業務擁有兩千餘家商業客户，終端覆蓋了全國三十一個省市，尤其是在北京、安徽、陝西、湖北、江蘇、河南等省具有較高的市場份額。
報吿期慢病業務收入同比增長4%。核心產品0號堅持學術推廣，開展多模式營銷，收入同比增長2%；復穗悦克服集採續約競爭加劇影響，集採續約新中標區域執標，收入同比增長60%；硝苯地平緩釋片(貝奇靈)和硝苯地平控釋片(貝奇康)挖掘集採紅利、發揮渠道功能，收入同比增長53%；厄貝沙坦分散片(豪降之)國採續約成功，收入同比增長113%；新併購天安藥業開展投後整合，深入挖掘業務協同點，二甲雙胍腸溶片收入同比增長23%。
專科業務收入同比增長11%。(1)受新生兒出生率下降和部分產品集採影響，兒科用藥領域收入基本持平，但核心產品珂立蘇和小兒氨基酸仍保持市場份額第一，公司正拓展新的兒科產品，加快新品導入；(2)腎科用藥領域收入同比增長14%，核心產品腹膜透析液廣東聯盟採中選，收入同比增長15%；(3)精神/神經領域銷售收入同比增長6%，核心產品丙戊酸鎂緩釋片收入同比增長1%，新產品普瑞巴林收入同比增長45%；(4)腫瘤領域收入同比增長75%，其中替尼泊苷收入同比增長73%，白消安收入同比增長100%。(5)女性健康領域收入同比增長12%，核心產品毓婷系列收入同比增長33%，在緊急避孕領域市場份額第一。
輸液業務收入同比增長3%。公司搶抓市場機會，基礎輸液收入同比增長9%，積極拓展新的治療性產品，加快產品結構調整。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
